SHENG Wanting , YANG Xiaohui , CHEN Jiaxin , JIN Lei , ZHU Huimin , LI Xiangyun , ZHAO Linfang
  • Department of Intravenous Therapy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, P. R. China;
ZHAO Linfang, Email: 3193159@zju.edu.cn
Cancer patients; Patient decision aids; Treatment decision; Overview of systematic reviews
10.7507/1672-2531.202401080
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective To overview the systematic reviews of the efficacy of cancer patient decision aids (PDAs) for treatment decision-making. Methods The PubMed, Web of Science, Cochrane Library, Embase, CINAHL, JBI, CNKI, VIP, CBM and WanFang Data databases were electronically searched to collect the systematic reviews relevant to the objective from inception to September 2023. Literature screening, data extraction, methodological quality assessment of the included literature, and summary and grading of the evidence were carried out independently by two researchers, and duplication of original studies in the included systematic evaluations was investigated using the corrected covered area (CCA). Results A total of 17 systematic reviews were included, of which 13 (76.47%) were low- or very low-quality studies. A total of 64 pieces of evidence were included, of which only 26 (40.62%) were of moderate quality, and the original studies included in the included literature had a low degree of overlap (CCA=0.05). The results of meta-analysis showed that PDAs could increase decision-related knowledge, reduce decision conflict and regret in cancer patients' treatment decision (P<0.05). But there was no significant difference on decision satisfaction, anxiety and depression (P>0.05). Conclusion PDAs can improve cancer patients' knowledge related to treatment decision, reduce decision conflicts and regrets, and have no significant negative effects on decision preparation, satisfaction, anxiety, and depression. However, the existing systematic reviews is of low quality and limited to a few cancer types.